NEW YORK (GenomeWeb News) – RNAi services firm Cenix BioScience said today that it has extended an existing collaboration with CellCentric to validate epigenetic oncology drug candidates.
The new project follows a pilot study that the companies began in March under which Cenix used its RNAi-based phenotypic characterization platform to study several of CellCentric’s drug target candidates in a diverse panel of human cell lines.
Under the expanded agreement, Cenix said it will use the same RNAi platform, along with proprietary high-content assays and Definiens’ Cellenger image analysis software, to analyze loss-of-function phenotypes for “several more” oncology target candidates across a new collection of human cell lines.
Further details of the collaboration were not disclosed.